T 
Touchstone International Medical Science Co 688013.SS · CNY
Health Care · Shanghai · 🇨🇳 China
20.73
-1.47%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥326.7m
FY2017FY2025
Net income
CN¥84.1m
FY2017FY2025
Free cash flow
−CN¥18.8m
FY2017FY2025
Shareholders' equity
CN¥565.6m
FY2017FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥326.7m | CN¥272.4m | CN¥253.6m | CN¥232.0m | CN¥213.7m | CN¥163.3m | CN¥172.8m | CN¥119.0m | CN¥89.6m |
| Research and development | CN¥51.3m | CN¥36.0m | CN¥35.3m | CN¥34.7m | CN¥29.3m | CN¥15.4m | CN¥14.1m | CN¥10.6m | CN¥8.2m |
| Operating income | CN¥94.2m | CN¥55.0m | CN¥46.4m | CN¥44.1m | CN¥44.9m | CN¥34.4m | CN¥45.6m | CN¥23.8m | CN¥13.7m |
| Net income | CN¥84.1m | CN¥51.9m | CN¥47.3m | CN¥43.2m | CN¥41.4m | CN¥34.9m | CN¥42.0m | CN¥23.1m | CN¥13.9m |
| Diluted earnings per share | 1.04 | 0.63 | 0.61 | 0.53 | 0.50 | 0.45 | 0.69 | 0.29 | 0.17 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥672.9m | CN¥637.2m | CN¥626.6m | CN¥543.5m | CN¥544.8m | CN¥485.2m | CN¥124.9m | CN¥117.0m | CN¥98.6m |
| Cash and short-term investments | — | CN¥395.1m | CN¥430.1m | CN¥362.3m | CN¥430.9m | CN¥379.3m | CN¥18.8m | CN¥18.5m | CN¥22.9m |
| Total liabilities | CN¥107.4m | CN¥55.8m | CN¥55.1m | CN¥35.0m | CN¥32.7m | CN¥19.4m | CN¥17.7m | CN¥34.1m | CN¥18.7m |
| Debt | CN¥14.1m | CN¥1.1m | CN¥2.0m | CN¥961,665 | — | — | — | CN¥9.0m | — |
| Shareholders' equity | CN¥565.6m | CN¥581.4m | CN¥571.5m | CN¥508.4m | CN¥512.1m | CN¥465.9m | CN¥107.2m | CN¥82.9m | CN¥79.8m |
| Shares outstanding | 81m | 82m | 78m | 82m | 83m | 77m | 61m | 81m | 81m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥72.0m | CN¥53.4m | CN¥82.9m | CN¥50.4m | CN¥61.0m | CN¥42.1m | CN¥34.8m | CN¥34.4m | CN¥7.9m |
| Capital spending | −CN¥90.7m | −CN¥41.9m | −CN¥18.4m | −CN¥47.7m | −CN¥9.2m | −CN¥7.3m | −CN¥9.4m | −CN¥20.8m | −CN¥15.2m |
| Free cash flow | −CN¥18.8m | CN¥11.5m | CN¥64.5m | CN¥2.7m | CN¥51.8m | CN¥34.8m | CN¥25.4m | CN¥13.7m | −CN¥7.3m |
| Dividends paid | −CN¥121.6m | −CN¥38.3m | −CN¥19.8m | −CN¥15.8m | −CN¥16.0m | −CN¥16.0m | −CN¥18.0m | −CN¥18.0m | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥57.7m | CN¥55.7m | CN¥82.9m | CN¥87.7m | CN¥90.3m | CN¥65.8m | CN¥70.3m | CN¥69.4m |
| Operating income | CN¥2.9m | CN¥5.4m | CN¥14.8m | CN¥26.3m | CN¥38.7m | CN¥14.6m | CN¥8.9m | CN¥15.0m |
| Net income | CN¥4.0m | CN¥9.7m | CN¥12.1m | CN¥23.7m | CN¥35.0m | CN¥13.2m | CN¥9.1m | CN¥13.9m |
| Diluted earnings per share | 0.05 | 0.12 | 0.15 | 0.29 | 0.43 | 0.16 | 0.11 | 0.17 |
| Cash from operations | — | — | — | CN¥27.0m | CN¥23.0m | CN¥13.0m | — | CN¥20.0m |
| Capital spending | −CN¥10.0m | −CN¥16.0m | −CN¥37.0m | −CN¥8.0m | −CN¥29.0m | −CN¥15.0m | −CN¥12.0m | −CN¥3.0m |
| Free cash flow | — | — | — | CN¥19.0m | −CN¥6.0m | −CN¥2.0m | — | CN¥17.0m |
| Total assets | CN¥664.4m | CN¥694.4m | CN¥672.9m | CN¥676.0m | CN¥640.8m | CN¥658.9m | CN¥637.2m | CN¥671.9m |
| Cash and short-term investments | — | — | — | CN¥350.6m | CN¥318.3m | CN¥372.7m | CN¥395.1m | CN¥429.7m |
| Debt | CN¥32.0m | CN¥8.6m | CN¥14.1m | CN¥17.3m | CN¥10.1m | CN¥20.1m | — | — |
| Shareholders' equity | CN¥494.8m | CN¥576.6m | CN¥565.6m | CN¥599.6m | CN¥574.4m | CN¥571.7m | CN¥581.4m | CN¥571.9m |
Financial ratios
Data as of 22 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 28.7% | 20.3% | 19.0% | 19.9% | 21.6% | 24.7% | — |
| Net margin | 25.7% | 19.1% | 18.7% | 18.6% | 19.4% | 21.4% | — |
| Return on equity | 14.9% | 8.9% | 8.3% | 8.5% | 8.1% | 7.5% | — |
| Return on assets | 12.5% | 8.1% | 7.6% | 7.9% | 7.6% | 7.2% | — |
| Free cash flow yield | 9.5% | 5.4% | 6.1% | 5.6% | 4.0% | 3.0% | — |
| Revenue growth | 20.0% | 7.4% | 9.3% | 8.6% | 30.9% | -5.4% | — |
| Earnings growth | 62.0% | 9.7% | 9.5% | 4.3% | 18.5% | -16.8% | — |
| Current ratio | 4.30x | 8.69x | 9.32x | 12.55x | 15.14x | 23.03x | — |
| Debt to equity | 0.02x | — | 0.00x | 0.00x | — | — | 0.11x |
| Equity ratio | 84.0% | 91.2% | 91.2% | 93.6% | 94.0% | 96.0% | — |
| Interest coverage | 198.10x | 146.99x | 247.18x | 168.63x | 632.67x | 409.01x | — |
| R&D as a share of sales | 15.7% | 13.2% | 13.9% | 15.0% | 13.7% | 9.4% | — |
| Buybacks as a share of market value | 2.2% | -5.7% | 4.4% | 1.2% | -7.2% | -26.1% | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 12.1% | 14.9% | — |
| Operating income | 28.8% | 22.4% | — |
| Net income | 24.9% | 19.2% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Price to earnings | 46.0 | 27.9 | 34.8 | 36.6 | 50.7 | 66.5 |
| Price to sales | 11.8 | 5.3 | 6.5 | 6.8 | 9.8 | 14.2 |
Dividends and splits
Per share, in the currency the company pays
Paid for 5 years. Last went ex-dividend on 26 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Paid in the year | 0.80 | 1.00 | 1.00 | 0.25 | 0.20 | 0.20 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.